Study of WVE-003 in Patients With Huntington's Disease
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, PK, and PD of WVE-003 in adult patients with
early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.